Trial Profile

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone (Primary) ; Apalutamide (Primary) ; Darolutamide (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms TRIPLE-SWITCH

05 Jun 2025 Status changed from not yet recruiting to recruiting.
22 Apr 2025 Planned initiation date changed from 30 Mar 2025 to 30 May 2025.
17 Feb 2025 Planned initiation date changed from 15 Jan 2025 to 30 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com